Catalyst Pharmaceuticals Appoints Daniel J. Brennan as Chief Commercial Officer
June 13 2018 - 8:03AM
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a
biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating, chronic
neuromuscular and neurological diseases, today announced the
appointment of Daniel J. Brennan as Chief Commercial Officer. Mr.
Brennan will be responsible for leading the Company’s marketing,
sales and commercial operations as Catalyst prepares for a
potential launch of Firdapse®.
“We are pleased to welcome Dan to the Catalyst
team, as he brings extensive experience in leading the commercial
efforts at biopharmaceutical companies, particularly those focused
on orphan, neurological diseases,” said Patrick J. McEnany,
Chairman and Chief Executive Officer of Catalyst Pharmaceuticals.
“Dan’s expertise in building commercial platforms is ideal as we
prepare for a potential approval of Firdapse in the second half of
this year.”
“I am very excited to join Catalyst at such a
key time for the Company, as we prepare to potentially
commercialize an FDA-approved treatment for the symptomatic
treatment of Lambert-Eaton myasthenic syndrome,” said Mr. Brennan.
“I look forward to joining the senior management team as we work to
bring life-changing treatments to patients with rare, debilitating
diseases.”
Mr. Brennan most recently served as the Chief
Operating Officer at Edge Therapeutics, where he was responsible
for pre-commercialization activities of the company’s lead product
targeting rare neurological conditions. Previously, Mr.
Brennan held several leadership positions at Lundbeck U.S.,
including Vice President and Group General Manager of Lundbeck’s
U.S. Neurology Business Unit and Business Development group.
Throughout his time in these positions, Lundbeck’s U.S. Neurology
group launched four specialty orphan products and achieved growth
in annual sales from $60 million to $820 million. Prior to
Lundbeck, Mr. Brennan was at Abbott Laboratories, where he served
as Divisional Vice President and General Management of the Acute
Care Hospital Business Unit, which was responsible for more than 80
commercial personnel and over $240 million in hospital-based
pharmaceutical sales. Mr. Brennan also served in various sales,
marketing and new product development roles of increasing
responsibility for Eli Lilly and Company from 1997 to 2007. Prior
to joining Edge Therapeutics in late 2016, Mr. Brennan served as
Chief Operating Officer and Executive Vice President of Insys
Therapeutics for approximately 8 months.
Mr. Brennan received a B.A. degree in Psychology
from the University of Notre Dame and an MBA degree, with
distinction, from the Kellogg Graduate School of Business at
Northwestern University.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical
company focused on developing and commercializing innovative
therapies for people with rare debilitating, chronic neuromuscular
and neurological diseases, including Lambert-Eaton myasthenic
syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK
antibody positive myasthenia gravis, spinal muscular atrophy (SMA)
type 3, and infantile spasms. Firdapse® (amifampridine phosphate)
has received Breakthrough Therapy Designation from the U.S. Food
and Drug Administration (FDA) for the treatment of LEMS and Orphan
Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse is
the first and only approved drug in Europe for symptomatic
treatment in adults with LEMS.
Catalyst is also developing CPP-115 to treat
refractory infantile spasms. CPP-115 has been granted U.S. Orphan
Drug Designation for the treatment of infantile spasms by the FDA
and has been granted E.U. Orphan Medicinal Product Designation for
the treatment of West syndrome by the European Commission. In
addition, Catalyst is developing a generic version of Sabril®
(vigabatrin).
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including (i) whether Firdapse will ever be
approved for commercialization, (ii) whether Catalyst will be the
first company to receive an approval for amifampridine (3,4-DAP),
giving it 5-year marketing exclusivity for its product, and (iii)
those other factors described in Catalyst's Annual Report on Form
10-K for the fiscal year 2017 and its other filings with the U.S.
Securities and Exchange Commission (SEC), could adversely affect
Catalyst. Copies of Catalyst's filings with the SEC are available
from the SEC, may be found on Catalyst's website, or may be
obtained upon request from Catalyst. Catalyst does not undertake
any obligation to update the information contained herein, which
speaks only as of this date.
Investor Contact
Brian Korb
Solebury Trout
(646) 378-2923
bkorb@troutgroup.com
Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024